WeTrials
Recruiting

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

What is this study?

This early-stage study tests a combination of two medications, osimertinib and carotuximab, for people with a specific type of advanced lung cancer. The main goal is to find the safest and most effective dose of this combination to help manage the disease better.

Who can participate?

You may be able to join if you are 18 or older, have advanced non-small cell lung cancer with a specific EGFR gene mutation, and have been taking osimertinib for less than 12 weeks. Your doctor will also check that you do not have certain past medical conditions or previous treatments that would affect the study.

What will happen?

Participants will receive the study medications and have their health closely monitored by the medical team to check for side effects and see how well the treatment works. This will include regular check-ins and tests, such as blood draws and tumor tissue checks, to track your progress.

Where and when?

This study is currently recruiting participants and takes place at medical locations in Beverly Hills and Los Angeles, California.

Key Points
  • 1Testing a combination of two cancer treatments for advanced lung cancer.
  • 2Focused on finding the right and safest dose for patients.
  • 3Currently recruiting patients at locations in California.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Non Small Cell Lung CancerLung Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.